Results from the phase 3 AEGEAN trial led to the approval of neoadjuvant and adjuvant durvalumab for patients with resectable NSCLC.
Approval Alert | Perioperative Durvalumab in Resectable NSCLC
Advertisement
Advertisement
Trending on CancerNetwork
1
Ficerafusp Alfa/Pembrolizumab Receives FDA BTD in Front-Line HNSCC
2
64Cu-SAR-bisPSMA PET Detects More Prostate Cancer Lesions vs SOC
3
FDA Grants Fast Track Designation to NG-350A For pMMR Rectal Cancer
4
How Will ESMO 2025 Data Shape the Future of Genitourinary Cancer Care?
5
